GlassScriptPhysician profile
Amanda Skelton
NPI 1346692035
$6,700.76
in general payments reported to CMS, 2019-2025
28 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $245 · 2024: $4,808 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,292 · Travel and Lodging: $1,261 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,291.64 |
| Travel and Lodging | $1,260.63 |
| Education | $148.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,713.33 | 2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $978.32 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $411.84 | 2024-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $318.77 | 2024-2025 | Briviact, Rystiggo, Fintepla |
| Emd Serono, INC. | $301.74 | 2023-2024 | Mavenclad |
| Sk Life Science, INC. | $288.89 | 2024-2025 | |
| Pfizer INC. | $286.61 | 2024-2025 | |
| Genentech USA, INC. | $282.69 | 2023-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Lundbeck LLC | $278.98 | 2023-2025 | Vyepti, Rexulti |
| Biogen, INC. | $274.93 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Eisai INC. | $189.93 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $181.00 | 2024 | Onpattro, Givlaari |
| Aucta Pharmaceuticals, INC. | $132.53 | 2024-2025 | Motpoly Xr |
| Grifols USA, LLC | $129.10 | 2024-2025 | Gamunex-C |
| Averitas Pharma INC. | $119.81 | 2024-2025 | Qutenza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $115.09 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Otsuka America Pharmaceutical, INC. | $108.35 | 2023-2025 | Rexulti, Nuedexta |
| Celgene Corporation | $99.72 | 2024-2025 | Zeposia |
| Jazz Pharmaceuticals INC. | $98.25 | 2024-2025 | |
| Argenx US, INC. | $96.27 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $57.82 | 2025 | Nuplazid |
| Neurelis, INC. | $55.87 | 2024-2025 | Valtoco |
| Ge Healthcare | $51.73 | 2024-2025 | |
| Octapharma USA, INC. | $35.52 | 2023 | Octagam Immune Globulin (Human) |
| Scilex Pharmaceuticals INC. | $35.22 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $24.51 | 2024 | Dysport |
| Axsome Therapeutics, INC. | $19.78 | 2025 | Symbravo |
| Kyowa Kirin, INC. | $14.16 | 2024 | Nourianz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Skelton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.